<i>SuFu</i> somatic mutations are recognized as novel markers for genomic instability and tumor growth in lung adenocarcinoma.

ABSTRACT:

Background

Lung adenocarcinoma (LUAD), the predominant histological subtype of non-small cell lung cancer, remains a leading cause of cancer-related mortality worldwide. Suppressor of fused (SuFu) protein, a key negative regulator of the Hedgehog (Hh) signaling pathway, exhibits context-dependent roles in cancer, functioning variably as an oncogene or tumor suppressor. While loss-of-function mutations in SuFu have been implicated in tumorigenesis across several cancer types, their clinical significance in LUAD remains unclear. The study aimed to explore SuFu's regulatory effects in LUAD and evaluate its clinical value as a biomarker.

Methods

Endogenous molecular data of SuFu in LUAD were obtained from public bioinformatics databases to investigate SuFu's impact on tumor muta

SUBMITTER: Liu JH 

PROVIDER: S-EPMC12605719 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature